Surufatinib10 Aug 2020 09:15
Fantastic news today regarding the EMA and Surufatinib registration. I tend to overlook the Europe and focus on what we are doing in the United States and China. I'm not sure what the size of the European market is for Oncology treatments, and probably need to research that a little, but it appears we could soon have Surufatinib submissions running concurrently in all 3 geographies.